Gene transfer into human hematopoietic stem cells continues to be complicated by issues of transfer efficiency. We have examined the capacity of newly described retroviral vectors based on the gibbon ape leukemia virus (GaLV) to introduce genes into human hematopoietic progenitor cells. Total nucleated human bone marrow cells were transduced using GaLV vectors packaged with either amphotropic or GaLV envelopes. Transduction efficiency was assayed by the generation of G418-resistant colony forming units. We found that GaLV vectors could transduce both BFU-E and CFU-C hematopoietic progenitors, and that their efficiency was at least equivalent to an amphotropically packaged Moloney mouse leukemia virus (MoMLV)-based vector. Moreover, vectors derived from the GaLV-SEATO strain and bearing amphotropic envelope were best for gene transfer into BFU-E, whereas vectors derived from the GaLV-SF strain and bearing GaLV envelope transduced CFU-C at higher efficiency. Thus, GaLV-based retroviral vectors are promising new tools for gene transfer into human hematopoietic cells.

Download full-text PDF

Source
http://dx.doi.org/10.1006/bbrc.1997.6130DOI Listing

Publication Analysis

Top Keywords

human hematopoietic
16
retroviral vectors
12
leukemia virus
12
gene transfer
12
hematopoietic progenitor
8
progenitor cells
8
vectors based
8
based gibbon
8
gibbon ape
8
ape leukemia
8

Similar Publications

Introduction: Hematologic malignancies, originating from uncontrolled growth of hematopoietic and lymphoid tissues, constitute 6.5% of all cancers worldwide. Various risk factors including genetic disorders and single nucleotide polymorphisms play a role in the pathogenesis of hematologic malignancies.

View Article and Find Full Text PDF

Despite the study of BCR::ABL1-positive and -negative myeloproliferative neoplasms (MPNs) providing seminal insights into cancer biology, tumor evolution and precision oncology over the past half century, significant challenges remain. MPNs are clonal hematopoietic stem cell-derived neoplasms with heterogenous clinical phenotypes and a clonal architecture which impacts the often-complex underlying genetics and microenvironment. The major driving molecular abnormalities have been well characterized, but debate on their role as disease-initiating molecular lesions continues.

View Article and Find Full Text PDF

[Clinical characteristics and prognosis of acute erythroleukemia in children].

Zhongguo Dang Dai Er Ke Za Zhi

January 2025

Department of Children's Hematology and Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Objectives: To investigate the clinical characteristics and prognosis of acute erythroleukemia (AEL) in children.

Methods: A retrospective analysis was conducted on the clinical data, treatment, and prognosis of 8 children with AEL treated at the First Affiliated Hospital of Zhengzhou University from January 2013 to December 2023.

Results: Among the 7 patients with complete bone marrow morphological analysis, 4 exhibited trilineage dysplasia, with a 100% incidence of erythroid dysplasia (7/7), a 71% incidence of myeloid dysplasia (5/7), and a 57% incidence of megakaryocytic dysplasia (4/7).

View Article and Find Full Text PDF

Objectives: To investigate the expression of soluble factor-related apoptosis ligand (sFasL) in peripheral blood and microRNA-147b (miR-147b) in monocytes in children with sepsis and their value in assessing prognosis.

Methods: A prospective study was conducted on 124 children with sepsis (sepsis group), 60 children with common infections (infection group), and 60 healthy children undergoing physical examinations (healthy control group). The independent risk factors for poor prognosis in children with sepsis were analyzed, and the value of serum sFasL and monocyte miR-147b in predicting poor prognosis in children with sepsis was assessed.

View Article and Find Full Text PDF

The clinical potential of current chimeric antigen receptor-engineered T (CAR-T) cell therapy is hampered by its autologous nature that poses considerable challenges in manufacturing, costs and patient selection. This spurs demand for off-the-shelf therapies. Here we introduce an ex vivo feeder-free culture method to differentiate gene-engineered hematopoietic stem and progenitor (HSP) cells into allogeneic invariant natural killer T (NKT) cells and their CAR-armed derivatives (CAR-NKT cells).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!